Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care

Hear expert insights on when to use interleukin inhibitors in the course of psoriatic arthritis.

Target Audience

This program is intended for rheumatology specialists including physicians and other healthcare providers who care for patients with psoriasis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the accumulating clinical study and real-world evidence regarding the efficacy and safety of IL-targeted biologics in patients with PsA who have had an inadequate response to conventional synthetic DMARDs
  • Describe the clinical results from recent studies that evaluated an interleukin blocker as initial therapy in patients with a new diagnosis of moderate to severe PsA

Additional Information

Partner: 
myCME
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
Course opens: 
12/29/2020
Course expires: 
12/28/2021
Rating: 
0

Vinod Chandran, MBBS, MD, DM, PhD
Associate Professor
Consultant Rheumatologist
Division of Rheumatology
Department of Medicine
University of Toronto
University Health Network
Toronto, Canada

Vinod Chandran, MBBS, MD, DM, PhD, has disclosed that he has received funds for research support from AbbVie and Amgen and consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB.

Alexis Ogdie, MD, MSCE
Associate Professor of Medicine and Epidemiology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Alexis Ogdie, MD, MSCE, has disclosed that she has received funds for research support from Amgen; consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Janssen, Gilead Sciences, Lilly, Novartis, and Pfizer; and other financial or material support from Novartis and Pfizer.

Staff

Zachary Schwartz, MSc
Scientific Director
Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report

Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report

Carolyn Skowronski, PharmD
Associate Director, Scientific Services
Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report

Megan Cartwright, PhD
Senior Clinical Editor
Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Provided by Clinical Care Options, LLC.

Physician Continuing Medical Education

Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
Please login or register to take this course.

This course is offered through MyCME. 

To take this course you will be redirected to MyCME's website. You must login or create an account with MyCME in order to complete this activity. 

Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!